Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 4/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1765041 | 0.95 | PPARG (0.44) | PPARGALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL1765111 | 0.86 | PPARG (0.35) | PPARGALDH1A1HPGDGAAKMT2A | |
| SCHEMBL1119946 | 0.86 | GAA (0.45) | PPARGALDH1A1HPGDKDM4EGAA | |
| SCHEMBL15230716 | 0.85 | GAA (0.38) | PPARGALDH1A1HPGDKDM4EGAA | |
| SCHEMBL15446675 | 0.84 | ALDH1A1 (0.43) | PPARGALDH1A1HPGDGAAKMT2A | |
| SCHEMBL1119900 | 0.83 | ALDH1A1 (0.36) | PPARGALDH1A1HPGDGAAMEN1 | |
| SCHEMBL1120023 | 0.83 | ALDH1A1 (0.34) | PPARGALDH1A1HPGDGAAKMT2A | |
| SCHEMBL1120218 | 0.82 | ALDH1A1 (0.35) | PPARGALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL15231257 | 0.82 | PPARG (0.38) | PPARGALDH1A1HPGDKDM4EGAA | |
| SCHEMBL15231208 | 0.82 | PPARG (0.37) | PPARGALDH1A1KDM4EGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124501-A1 | Active compound combinations | BAYER CROPSCIENCE AG (DE) | 2011-05-26 | — | — | US | claimed |
| WO-2011051243-A1 | ACTIVE COMPOUND COMBINATIONS | BAYER CROPSCIENCE AG (DE) | 2011-05-05 | — | — | WO | claimed |
| US-20110124501-A1 | Active compound combinations | BAYER CROPSCIENCE AG (DE) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124501-A1 | Active compound combinations | CYP51A1, CA4, BROX | PPARG 402/4885ALDH1A1 240/4885HPGD 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.